



Anthem Biosciences IPO

Anthem Biosciences Ltd

₹14,040

/26 shares

Minimum Investment

Listed on 21 Jul '25

Anthem Biosciences IPO Listing Details

Listed On	Issue Price	Listing Price	Listing Gains
BSE	₹570.00	₹723.05	₹153.05 (26.85%)

Anthem Biosciences

160.2

TRADE SHARES

Anthem Biosciences IPO Details

Bidding Dates	Min. Investment	Lot Size	Price Range
14 Jul '25 - 16 Jul '25	₹14,040	26	₹540 - ₹570
Issue Size	IPO Doc		
3395.00Cr	RHP PDF		

Subscription rate As of 16 Jul'25, 05:00 PM

Qualified Institutional Buyers	182.65x
Non-Institutional Investor	42.31x
Retail Individual Investor	5.48x
Employees	6.36x
Total	63.77x

About Anthem Biosciences

Anthem Biosciences is a contract research, development, and manufacturing organisation (CRDMO) based in India, specialising in integrated services across drug discovery, development, and manufacturing. The company offers a broad range of services, including the development of new chemical entities (NCEs) and new biological entities (NBEs), with capabilities in RNA interference, antibody-drug conjugates, peptides, lipids, and oligonucleotides. They support global clients, including biotech and pharmaceutical companies, from early-stage discovery through to commercial manufacturing. The company operates three manufacturing facilities: Unit I in Bommassandra, Unit II, and Unit III in Harohalli, in Karnataka. Unit III is currently under construction and is expected to be operational in 2025.

[Read less](#)

Founded in	2006
Managing director	Mr Ajay Bhardwaj
Parent organisation	Anthem Biosciences Ltd

Anthem Biosciences IPO ...



Anthem Biosciences Ltd IPO

https://www.youtube.com/watch?v=6EZNd_bMyM

Strengths & Financials of Anthem Biosciences

Strengths

Risks



Anthem Biosciences claims to have comprehensive, integrated service capabilities across the entire drug lifecycle, including drug discovery, development, and manufacturing. It further states that it is one of the few Indian CRDMOs with strong capabilities in both small molecules and biologics (large molecules). The company claims this allows it to provide customised solutions to a range of clients, reducing lead times and offering cost efficiencies throughout the drug development process.



Anthem Biosciences claims to have developed a broad range of advanced technological solutions across various modalities, including RNA interference, antibody-drug conjugates, peptides, lipids, and oligonucleotides. The company further states that it is recognised for introducing biotransformation and flow chemistry techniques in India and has become one of the pioneers in using green chemistry methods to improve manufacturing efficiency and reduce waste.



Anthem Biosciences claims to have a differentiated business model specifically designed to cater to the needs of small pharmaceutical and emerging biotech companies. By providing end-to-end services from drug discovery to commercial manufacturing, it claims to support these companies in overcoming challenges such as regulatory compliance, funding, and scaling up manufacturing. The company further states that its success-based fee-for-service (FFS) model, with a 96.76 percent success rate as of FY25, allows it to deliver cost-effective, high-quality solutions, contributing to higher margins and long-term partnerships with these emerging players.



The company claims to have developed long-term relationships with 287 customers, including small biotech firms, mid-sized pharmaceutical companies, and large multinational corporations like Bayer AG.



The company claims to have a broad and diversified specialty ingredients portfolio, with expertise in producing high-demand niche ingredients such as glucagon-like peptide-1 (GLP-1), fermentation-based products, probiotics, enzymes, and biosimilars. By leveraging its advanced technological capabilities in both biology and chemistry, Anthem Biosciences claims to have successfully commercialised several products, including natural Vitamin K2 and probiotics.



The company claims to operate state-of-the-art, current good manufacturing practice (cGMP) compliant manufacturing facilities in India, featuring the largest fermentation capacity of any Indian CRDMO. These facilities are highly automated, incorporating advanced systems like distributed control systems (DCS) to reduce manual intervention and enhance quality output.



The company holds ISO 9001:2015 certification for its quality management systems, ISO 14001:2015 certification for its environmental management systems, and ISO 45001:2018 certification for its occupational health and safety management systems.



The company reported a consistent increase in revenue from operations. It increased from Rs 1,056.92 crore in FY23 to Rs 1,419.37 crore in FY24 and Rs 1,844.55 crore in FY25.

Anthem Biosciences Financials



Application Details of Anthem Biosciences IPO

Apply as	Price band	Apply upto
Regular	₹540 - 570	₹2 Lakh
Employee	₹490 - 520	₹2 Lakh
High Networth Individual	₹540 - 570	₹2 - 5 Lakh

For Anthem Biosciences IPO, eligible investors can apply as Regular & Employee.

Top Anthem Biosciences IPO FAQs

- What is the issue size of Anthem Biosciences Ltd IPO?▼
- What is 'pre-apply' for Anthem Biosciences Ltd IPO?▼
- If I pre-apply for Anthem Biosciences Ltd IPO, when will my order get placed?▼
- When will I know if my Anthem Biosciences Ltd IPO order is placed?▼
- What are the open and close dates of the Anthem Biosciences Ltd IPO?▼
- What is the lot size and minimum order quantity of the Anthem Biosciences Ltd IPO?▼
- What is the allotment date for the Anthem Biosciences Ltd IPO?▼
- Who is the registrar of Anthem Biosciences Ltd IPO?▼
- Where is the Anthem Biosciences Ltd IPO getting listed?▼

Home > IPO > Anthem Biosciences Ltd



Vaishnavi Tech Park, South Tower, 3rd Floor
Sarjapur Main Road, Bellandur, Bengaluru - 560103
Karnataka

Contact Us



GROWW

- About Us
- Pricing
- Blog
- Media & Press
- Careers
- Help & Support
- Trust & Safety

PRODUCTS

- Stocks
 - Groww Terminal
 - Stocks Screener
 - Algo Trading
- F&O
- MTF
- ETF
- IPO
- Credit
- Mutual Funds
 - Groww Digest
 - Demat Account
 - Groww AMC

Share Market	Indices	F&O	Mutual Funds	Funds By Groww	Calculators	IPO	Miscellaneous
Top Gainers Stocks	Top Losers Stocks	Most Traded Stocks	Stocks Feed	FII DII Activity			
52 Weeks High Stocks	52 Weeks Low Stocks	Stocks Market Calender	Suzlon Energy	IRFC			
Tata Motors	IREDA	Tata Steel	Zomato (Eternal)	Bharat Electronics			
NHPC	State Bank of India	Tata Power	Yes Bank	HDFC Bank			
ITC	Adani Power	Bharat Heavy Electricals	Infosys	Vedanta			
Wipro	CDSL	Indian Oil Corporation	NBCC	Reliance Power			
Show More							